Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.38 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946390 | 0.84 | KCNH2 (0.40) | KCNH2CYP8B1 | |
| SCHEMBL4069340 | 0.82 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL13238486 | 0.81 | DRD2 (0.46) | KCNH2CYP8B1 | |
| SCHEMBL2955102 | 0.80 | CYP8B1 (0.39) | KCNH2CYP8B1 | |
| Hydrochloric Acid SCHEMBL4069318 | 0.78 | EHMT2 (0.46) | KCNH2CYP8B1 | |
| SCHEMBL5548608 | 0.77 | CYP8B1 (0.37) | KCNH2CYP8B1 | |
| SCHEMBL2951476 | 0.76 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL1223922 | 0.75 | NCF1 (0.40) | KCNH2CYP8B1CCR8 | |
| SCHEMBL1224706 | 0.75 | CYP8B1 (0.44) | CYP8B1 | |
| SCHEMBL2949221 | 0.75 | KCNH2 (0.52) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759340-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759340-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759340-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7648984-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-01-19 | — | — | US | disclosed |
| US-7605169-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-10-20 | — | — | US | disclosed |
| US-7592334-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20090181955-A1 | Antibacterial Agents | MILLER WILLIAM HENRY | 2009-07-16 | — | — | US | disclosed |
| US-20090181955-A1 | Antibacterial Agents | MILLER WILLIAM HENRY | 2009-07-16 | — | — | US | disclosed |
| US-20080139539-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139539-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080009483-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| EP-1846411-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-10-24 | — | — | EP | disclosed |
| US-20070203127-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20060189601-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| WO-2006081289-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | KCNH2 3440/4885CYP8B1 252/4885CCR8 2250/4885 |
| US-20080139539-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | KCNH2 3002/4885CYP8B1 2143/4885CCR8 4401/4885 |
| US-20060189601-A1 | Antibacterial agents | NQO2, NRDC, IFNG | KCNH2 3365/4885CYP8B1 1990/4885CCR8 4418/4885 |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | KCNH2 1741/4885CYP8B1 3751/4885CCR8 4690/4885 |
| US-20090181955-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | KCNH2 3002/4885CYP8B1 2143/4885CCR8 4401/4885 |
| US-20080009483-A1 | Antibacterial Agents | NRDC, NISCH, NAPRT | KCNH2 1712/4885CYP8B1 1769/4885CCR8 2918/4885 |
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | KCNH2 2586/4885CYP8B1 965/4885CCR8 3855/4885 |
| US-20070203127-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | KCNH2 2586/4885CYP8B1 965/4885CCR8 3855/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | KCNH2 2586/4885CYP8B1 965/4885CCR8 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.